To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Foreword Axel S Merseburger is the Professor and Chairman of the Department of Urology in Lübeck, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis. He completed a residency in surgery and urology at the Eberhard Karls University in Tübingen, Germany, and was a Research Fellow at the Miller School of Medicine, Miami, USA, in 2006. Professor Merseburger accepted a position as a staff member in Hannover in 2008 and was promoted to Associate Professor in 2009 and full Professor in 2012. Professor Merseburger is board certified in urology and urological oncology and is a member of numerous national and international urological and oncological associations, as well as serving as a reviewer and member of the editorial board for many journals. Professor Merseburger is Editor-in-Chief of the Advanced Prostate Cancer Resource Centre and Associate Editor of the World Journal of Urology. Furthermore, he is a member of the European Association of Urology (EAU) Guideline Group for Renal Cancer. Professor Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has published more than 200 papers in peer-reviewed journals. His main area of interest is urological oncology. Professor Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in international Phase II and III trials. W elcome to the latest edition of European Oncology & Haematology, which features a wide variety of topical articles of interest to oncologists and haematologists as well as the wider medical community. We begin with a review by Pérol of the treatment of advanced non-small cell lung cancer (NSCLC). Thanks to the advances in therapies that target single oncogenic alterations, as well as the advent of immune checkpoint inhibitors, personalised treatment has revolutionised NSCLC therapy. Prostate cancer is another area of groundbreaking clinical progress in recent years. Hennig, Gilbert and Merseburger review the latest clinical developments in the field of advanced prostate cancer. Despite the availability of screening and vaccination programmes, cervical cancer represents a significant global health burden. Oaknin and Rodriguez-Freixinos review therapies that target angiogenesis, with a focus on bevacizumab, the first targeted agent to be granted regulatory approval by the US Food and Drug Administration for use alongside chemotherapy. Large-scale sequencing of cancer genomes has now been completed for thousands of cancer samples. This has advanced our understanding of the genomic, biological and clinical features of myelodysplastic syndromes (MDS). In an editorial, Montalban- Bravo and Garcia-Manero discuss the molecular basis of this heterogeneous group of chronic haematological malignancies and its implications for new therapeutic agents. Also on the subject of haematological disease, Cappellini et al. celebrate the 10-year anniversary of the Sherlock Holmes symposia by describing a number of clinical cases of rare haematological disorders. Addressing the needs of our ageing population is becoming more important as the ‘baby boomers’ reach retirement age, with a projected rise in cancer by the America Society of Clinical Oncology (ASCO) as the top cancer advance of 2016 to provide care tailored to the individual. Conversely, the rate of childhood cancer caused by genetic predisposition remains high (around 8.5%). Bourdeaut discusses the impact of next generation sequencing (NGS), in particular the moral implications of parents knowing that their unborn baby carries a deleterious mutation. Two articles discuss recent advances in breast cancer. Belagali et al review the optimal use of fulvestrant, an oestrogen-receptor antagonist, in the management of hormone-receptor positive breast cancer. In addition Teixeira et al describes the applications of NGS in breast cancer. Identification of driver mutations opens the door to new targeted therapies and diagnostic tools. Many cancer therapies are, by necessity, aggressive and are associated with toxicities that require careful management. An article by Eriksen and Merlano discusses one such therapy: hyperfractionated radiotherapy with concurrent cisplatin in HPV/p16 negative head and neck cancer. Finally, we focus on immunotherapy, which is also associated with significant toxicity. van Eeden and Bernardo L Rapoport review the supportive care of patients undergoing immunotherapy. European Oncology & Haematology would like to thank our Editorial Board for their continuing support and guidance. A special thanks also goes to our authors, who gave their time and effort to produce an insightful selection of articles. The expert discussions and the range of topics covered ensure there is something of interest for every reader and we hope you find this edition useful. n TOU CH MED ICA L MEDIA 9